NEW YORK, NY / ACCESSWIRE / April 18, 2017 /The volatile Biotech Industry has continued to be home to some of the largest gainers on the market in 2017. President Trump's pledge for a faster FDA approval process has already paid dividends for the industry as the FDA has already approved 13 new drugs in 2017, compared to just 22 new drug approvals in 2016. The iShares NASDAQ Biotechnology Index ETF and SPDR S&P Biotech ETF have posted gains of 9.5 percent and 16.25 percent, respectively, year-to-date.
Sarepta Therapeutics Inc.https://ub.rdinvesting.com/news/?ticker=SRPT
TG Therapeutics Inc.https://ub.rdinvesting.com/news/?ticker=TGTX
Sarepta Therapeutics' shares gained 2.84 percent to close at $30.78 a share on Monday. The stock traded between $29.84 and $31.35 on volume of 1.49 million shares traded. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. Sarepta is scheduled to release results for the first quarter of 2017 after market close on Thursday, April 27th. The company reported a loss of $1.62 per share on revenues of $5.42 million in the fourth quarter of 2016. Shares of Sarepta Therapeutics have gained approximately 12.21 percent year-to-date.
Access RDI's Sarepta Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=SRPT
TG Therapeutics' shares increased 6.06 percent to close at $10.50 a share on Monday. The stock traded between $9.85 and $10.69 on volume of 1.39 million shares traded. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. On April 5th, TG Therapeutics presented preclinical data on the company's novel fully human anti-PD-L1 monoclonal antibody at the American Association for Cancer Research (AACR) annual meeting in Washington D.C. Shares of TG Therapeutics have gained approximately 125.81 percent year-to-date.
Michael S. Weiss, the Company's Executive Chairman and CEO stated, "The team has worked hard to develop a high quality anti-PD-L1 antibody which we believe is the cornerstone of any proprietary immune-oncology (I/O) strategy. While anti-PD-1/PD-L1 therapy has been broadly explored in solid tumors, we are still in the very early days of understanding their utility and best applications in B-cell malignancies."
Access RDI's TG Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=TGTX
Our Actionable Research on Sarepta Therapeutics Inc. (NASDAQ: SRPT) and TG Therapeutics Inc. (NASDAQ: TGTX) can be downloaded free of charge at Research Driven Investing.
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.